Loading…

Central nervous system melioidosis in the pediatric age group: review

Purpose Melioidosis is a potentially fatal infectious disease caused by Burkholderia pseudomallei . Neurologic involvement in pediatric age group is very rare, and only a handful of cases have been reported in literature. We sought to provide a systematic review of pediatric neurologic melioidosis....

Full description

Saved in:
Bibliographic Details
Published in:Child's nervous system 2017-06, Vol.33 (6), p.1-6
Main Authors: Prasad, G Lakshmi, Kini, Pushpa, Divya S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Melioidosis is a potentially fatal infectious disease caused by Burkholderia pseudomallei . Neurologic involvement in pediatric age group is very rare, and only a handful of cases have been reported in literature. We sought to provide a systematic review of pediatric neurologic melioidosis. Methods Literature review was performed to analyze reported cases of pediatric neurologic melioidosis (≤16 years) by searching online database (PubMed/MEDLINE). Results Twenty-seven cases were analyzed. Mean age was 6.7 years (range 2 days–14 years) and around 50% were older children (>5 years). Cranial nerve palsies and fever were most common presenting features. Major manifestations were meningoencephalitis in 16 (59%) and cerebral abscesses in eight (29%) cases. Abscesses were mostly located in parietal lobe. Among older children, abscesses were common than meningeal disease, while being converse for neonates. Mean follow-up duration was 11.5 months. Ten cases showed good to excellent outcome, while eight cases had fair (incomplete recovery) outcomes. The overall mortality rate was 18.5% (5/27) and tends to decrease with age. Among the five deaths, 4 (80%) had septicemia or pneumonia. Conclusions Pediatric neurologic melioidosis is very rare. Meningoencephalitis is the most common presentation. Mortality is the highest in neonates. Ceftazidime appears to be the drug of choice in intensive phase, although the best drug in maintenance phase cannot be commented upon, especially in very young children.
ISSN:0256-7040
1433-0350
DOI:10.1007/s00381-017-3422-1